AKU logo

Akumin Inc. (AKU) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Akumin Inc. (AKU) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 53/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 53/100

Akumin Inc. (AKU) Resumen de Asistencia Médica y Tuberías

CEORiadh Zine-El-Abidine
Empleados1737
Sede CentralPlantation, US
Año de la oferta pública inicial (OPI)2020

Akumin Inc. delivers outpatient diagnostic imaging services in the U.S., offering radiology and oncology solutions to hospitals and health systems. With a network of 200 locations, the company provides MRI, CT, and other imaging modalities. Despite negative profitability, Akumin plays a crucial role in healthcare diagnostics.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Akumin Inc. presents a complex investment case. While the company plays a vital role in providing outpatient diagnostic imaging services, its financial performance raises concerns. With a market capitalization of $0.03 billion and a negative P/E ratio of -0.17, the company's profitability is a significant challenge, further highlighted by a negative profit margin of -20.2%. The company's gross margin stands at 18.8%. Potential growth catalysts include expanding its network of imaging locations and increasing service offerings. However, the company must address its profitability issues to ensure long-term sustainability. Investors should closely monitor Akumin's ability to improve its financial performance and capitalize on growth opportunities in the diagnostic imaging market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Akumin operates approximately 200 owned and/or operated imaging locations across the United States.
  • The company provides services to approximately 1,000 hospitals and health systems in 46 states.
  • Akumin's market capitalization is $0.03 billion, reflecting its current market valuation.
  • The company's P/E ratio is -0.17, indicating negative earnings.
  • Akumin's profit margin is -20.2%, highlighting profitability challenges.

Competidores y Pares

Fortalezas

  • Extensive network of imaging centers.
  • Established relationships with hospitals and health systems.
  • Comprehensive range of diagnostic imaging services.
  • Presence in multiple states across the United States.

Debilidades

  • Negative profit margin.
  • High debt levels.
  • Dependence on reimbursement rates.
  • Competition from larger imaging providers.

Catalizadores

  • Ongoing: Expansion of imaging center network through acquisitions and new site development.
  • Ongoing: Implementation of new technologies to improve diagnostic accuracy and efficiency.
  • Upcoming: Potential partnerships with healthcare providers to expand referral network.
  • Upcoming: Focus on oncology services to capitalize on growing demand for cancer diagnostics and treatment.

Riesgos

  • Ongoing: Changes in reimbursement policies affecting revenue and profitability.
  • Ongoing: Increased competition from other imaging providers.
  • Potential: Economic downturn affecting healthcare spending.
  • Potential: Technological obsolescence requiring significant capital investment.
  • Potential: Integration risks associated with acquisitions.

Oportunidades de crecimiento

  • Expansion of Service Offerings: Akumin can expand its service offerings to include more specialized diagnostic procedures and interventional radiology services. This would allow the company to attract a broader range of patients and increase revenue per location. The market for specialized diagnostic services is growing, driven by advancements in medical technology and increasing demand for personalized medicine. Timeline: 1-2 years. Market Size: $10 billion annually.
  • Strategic Acquisitions: Akumin can pursue strategic acquisitions of smaller imaging centers and radiology practices to expand its geographic footprint and market share. This would allow the company to enter new markets and consolidate its position in existing markets. The market for imaging center acquisitions is active, with numerous opportunities available. Timeline: Ongoing. Market Size: $5 billion annually.
  • Technological Upgrades: Investing in advanced imaging technologies, such as AI-powered diagnostic tools and high-resolution imaging systems, can improve the accuracy and efficiency of Akumin's services. This would allow the company to attract more patients and improve patient outcomes. The market for advanced imaging technologies is growing rapidly. Timeline: 1-3 years. Market Size: $3 billion annually.
  • Partnerships with Healthcare Providers: Akumin can form strategic partnerships with hospitals, physician groups, and other healthcare providers to expand its referral network and increase patient volume. This would allow the company to access a larger pool of patients and integrate its services into the broader healthcare ecosystem. Timeline: Ongoing. Market Size: $2 billion annually.
  • Focus on Oncology Services: Akumin can focus on expanding its oncology services, such as PET/CT imaging and radiation therapy, to capitalize on the growing demand for cancer diagnostics and treatment. This would allow the company to tap into a high-growth market segment and improve its profitability. The market for oncology services is growing rapidly. Timeline: 2-3 years. Market Size: $7 billion annually.

Oportunidades

  • Expansion into new geographic markets.
  • Increased demand for outpatient imaging services.
  • Technological advancements in diagnostic imaging.
  • Partnerships with healthcare providers and payers.

Amenazas

  • Changes in reimbursement policies.
  • Increased competition from other imaging providers.
  • Economic downturn affecting healthcare spending.
  • Technological obsolescence.

Ventajas competitivas

  • Extensive network of approximately 200 imaging locations.
  • Relationships with approximately 1,000 hospitals and health systems.
  • Comprehensive suite of diagnostic imaging services.
  • Established presence in 46 states across the United States.

Acerca de AKU

Akumin Inc., founded in 2015 and headquartered in Plantation, Florida, is a prominent provider of outpatient diagnostic imaging services in the United States. The company operates through two primary segments: Radiology and Oncology. Akumin offers a comprehensive suite of medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and various other diagnostic and interventional radiology procedures. These services are delivered through a network of approximately 200 owned and/or operated imaging locations. Akumin's services cater to a broad spectrum of healthcare needs, supporting the diagnostic and treatment pathways for numerous medical conditions. The company partners with approximately 1,000 hospitals and health systems across 46 states, providing them with outpatient radiology and oncology services and solutions. This extensive network allows Akumin to reach a significant patient population and contribute to the efficiency and effectiveness of healthcare delivery. The company's focus on outpatient services aims to provide convenient and cost-effective access to essential diagnostic imaging, reducing the burden on hospital resources and improving patient outcomes. Akumin's commitment to innovation and quality in diagnostic imaging has positioned it as a key player in the evolving healthcare landscape.

Qué hacen

  • Provides outpatient diagnostic imaging services.
  • Offers magnetic resonance imaging (MRI) services.
  • Performs computed tomography (CT) scans.
  • Conducts positron emission tomography (PET) scans.
  • Offers nuclear medicine services.
  • Provides mammography and ultrasound services.
  • Delivers digital radiography and fluoroscopy procedures.
  • Offers interventional radiology procedures.

Modelo de Negocio

  • Generates revenue by providing diagnostic imaging services to patients.
  • Contracts with hospitals and health systems to provide outpatient radiology and oncology solutions.
  • Operates a network of owned and/or operated imaging locations.
  • Focuses on outpatient services to provide convenient and cost-effective access to diagnostic imaging.

Contexto de la Industria

The medical diagnostics and research industry is experiencing growth driven by technological advancements, an aging population, and increasing prevalence of chronic diseases. Companies like Akumin play a crucial role in providing essential diagnostic imaging services. The industry is competitive, with players like ABDXF (Abdos Healthcare), AWH (American WholeHealth), CNTG (Centogene), DMTKQ (DMC Global Inc.), and LMDX (Lantheus Holdings) vying for market share. Market trends include a shift towards outpatient services, increasing demand for advanced imaging modalities, and the integration of AI and machine learning to improve diagnostic accuracy and efficiency.

Clientes Clave

  • Hospitals and health systems across the United States.
  • Physician groups and medical practices.
  • Patients requiring diagnostic imaging services.
  • Oncology centers and cancer treatment facilities.
Confianza de la IA: 81% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Akumin Inc. (AKU): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AKU.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para AKU.

MoonshotScore

53/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de AKU en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Riadh Zine-El-Abidine

CEO

Riadh Zine-El-Abidine is the Chief Executive Officer of Akumin Inc. He has extensive experience in the healthcare industry, with a focus on diagnostic imaging and healthcare management. His career includes leadership roles in various healthcare organizations, where he has been responsible for strategic planning, operational management, and business development. He is known for his expertise in driving growth and improving operational efficiency. His leadership is focused on expanding Akumin's market presence and enhancing its service offerings.

Historial: Under Riadh Zine-El-Abidine's leadership, Akumin Inc. has focused on expanding its network of imaging centers and strengthening its relationships with hospitals and health systems. He has overseen the implementation of new technologies and services to improve patient care and operational efficiency. Key milestones include strategic acquisitions and partnerships aimed at increasing market share and enhancing the company's competitive position. His focus remains on improving financial performance and driving sustainable growth.

Acciones de Akumin Inc.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar AKU?

Akumin Inc. (AKU) actualmente tiene una puntuación IA de 53/100, indicando puntuación moderada. Fortaleza clave: Extensive network of imaging centers.. Riesgo principal a monitorear: Ongoing: Changes in reimbursement policies affecting revenue and profitability.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de AKU?

AKU actualmente puntúa 53/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de AKU?

Los precios de AKU se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre AKU?

La cobertura de analistas para AKU incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en AKU?

Las categorías de riesgo para AKU incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Changes in reimbursement policies affecting revenue and profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de AKU?

La relación P/E para AKU compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está AKU sobrevalorada o infravalorada?

Determinar si Akumin Inc. (AKU) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de AKU?

Akumin Inc. (AKU) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • AI analysis pending for AKU. Financial data based on available information as of 2026-03-16.
Fuentes de datos

Popular Stocks